Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2023-12, Vol.87 (6), p.524-537
Main Authors: Fenwick, Craig, Turelli, Priscilla, Duhoo, Yoan, Lau, Kelvin, Herate, Cécile, Marlin, Romain, Lamrayah, Myriam, Campos, Jérémy, Esteves-Leuenberger, Line, Farina, Alex, Raclot, Charlène, Genet, Vanessa, Fiscalini, Flurin, Cesborn, Julien, Perez, Laurent, Dereuddre-Bosquet, Nathalie, Contreras, Vanessa, Lheureux, Kyllian, Relouzat, Francis, Abdelnabi, Rana, Leyssen, Pieter, Lévy, Yves, Pojer, Florence, Stahlberg, Henning, Le Grand, Roger, Trono, Didier, Pantaleo, Giuseppe
Format: Article
Language:English
Subjects:
ACE2 mimetic
Angiotensin-Converting Enzyme 2
Animals
Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
COVID-19
Epitopes
Haplorhini
Human health and pathology
Humans
Immunology
Infectious diseases
Life Sciences
Neutralizing antibodies
Omicron
SARS-CoV-2
Spike Glycoprotein, Coronavirus - genetics
Variants of concern
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide prophylactic protection to immunocompromised patient populations. Spike-specific B-cell clones isolated from a vaccinated post-infected donor were profiled for those producing potent neutralizing antibodies against a panel of SARS-CoV-2 variants. The P4J15 antibody was further characterized to define the structural binding epitope, viral resistance, and in vivo efficacy. The P4J15 mAb shows
ISSN:0163-4453
1532-2742
1532-2742
DOI:10.1016/j.jinf.2023.10.008